Trials / Terminated
TerminatedNCT00597116
An Efficacy and Safety Study With Vandetanib to Treat Inoperable or Relapsed Malignant Mesothelioma
A Randomized Phase II Trial To Evaluate The Efficacy And Safety Of Vandetanib (ZD6474, ZACTIMA ™) Versus Vinorelbine In Patients With Inoperable Or Relapsed Malignant Mesothelioma.
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- Genzyme, a Sanofi Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A clinical study to assess if a new investigational drug is effective in treating malignant mesothelioma, compared to a chemotherapy treatment (Navelbine®). In this study the patients will be assigned by chance to receive either the new drug or a chemotherapy treatment (Navelbine®). Treatment will continue as long as the cancer does not worsen and the patient wishes to continue in the study. The study will recruit approximately 66 patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Vinorelbine | |
| DRUG | Vandetanib | once daily oral dose |
Timeline
- Start date
- 2007-12-01
- Primary completion
- 2010-01-01
- Completion
- 2010-01-01
- First posted
- 2008-01-17
- Last updated
- 2016-10-10
- Results posted
- 2012-10-15
Locations
6 sites across 2 countries: Germany, Switzerland
Source: ClinicalTrials.gov record NCT00597116. Inclusion in this directory is not an endorsement.